GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025
Opening of AAC targeted for Q4 2025 at the latest
Multiple near-term value catalysts expected over next 12 months
PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study.
Clear Path Forward for LUMEVOQ® AAC Program in France
Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025.
In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest.
"In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment."
Financing Strategy to Support Regulatory Milestones
GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones.
"We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. "
Advancing Core Marketing Authorization Strategy
In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy:
Preparation for regulatory consultations in the US and EU
Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements
Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply
Advancing preparations for MHRA submission in the United Kingdom
During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities.
Multiple Value Catalysts
GenSight anticipates a number of significant value-creating events in 2025-2026:
Q3 2025: Clinical trial application for focused dose-ranging study
Q4 2025: Completion of manufacturing tech transfer
Q4 2025: Opening of the AAC program
Q2 2026: Completion of Phase III trial preparations
Early H2 2026: Initiation of global Phase III clinical trial
Early H2 2026: pre-submission meeting with MHRA
Financial Position
The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025.
The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®.
As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares.
Risk factors
Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website (www.gensight-biologics.com) and/or AMF (www.amf-france.org). The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612867666/en/
Contacts
GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@gensight-biologics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
21 minutes ago
- Bloomberg
Cargill's Revenue Falls to 4-Year Low Amid Declining Crop Prices
Cargill Inc. 's revenue declined to the lowest in four years as the largest private company in the US continues to restructure in the face of declining crop prices and a shrinking American cattle herd. The Minneapolis-based company posted revenue of $154 billion in the year ended May 31, according to an annual report posted on its website. That's down from about $160 billion a year earlier and the lowest since 2021, when revenue was reported at $134 billion.
Business Wire
an hour ago
- Business Wire
Deadline Approaching: Lineage, Inc. (LINE) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Lineage, Inc. ('Lineage' or the 'Company') (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement used in connection with the Company's July 2024 initial public offering (the 'IPO'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LINEAGE, INC. (LINE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? In July 2024, Lineage conducted its IPO, selling over 65 million shares of common stock at $78 per share. On November 6, 2024, Lineage released its third quarter 2024 financial results, revealing that it had suffered a $543 million net loss during the quarter. On this news, Lineage's stock price fell $5.22, or 7.4%, to close at $65.79 per share on November 6, 2024, thereby injuring investors. Then, on January 14, 2025, The Wall Street Journal reported that Lineage was laying off employees due to reduced customer demand only six months after its IPO. Then, on April 7, 2025, Lineage announced the dismissal of its auditor, KPMG LLP. On this news, Lineage's stock price fell $5.29, or 9.9%, over two consecutive trading days, to close at $48.41 per share on April 8, 2025. Then, on April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.16, or 14.62%, to close at $47.65 per share on April 30, 2025, thereby injuring investors further. On June 3, 2025, the Company stated at an Investor Conference that there has been 'pretty much flat demand' for Lineage's products and services and that the Company was operating in a 'flattish environment' in terms of demand. The price of Lineage stock has remained substantially below the IPO price at the time of this complaint's filing. What Is The Lawsuit About? The complaint filed in this class action alleges that the Registration Statement made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, the Company's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and the Company's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) that Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing the Company; (3) that Lineage was unable to effectively counteract the adverse trends listed in the foregoing through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) that, as a result of the foregoing, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the Registration Statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Lineage common stock pursuant and/or traceable to the IPO, you may move the Court no later than September 30, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Insider
an hour ago
- Business Insider
Beta Glass records impressive 63% revenue surge in half-year results, as PBT rises by 337%
#FeaturedPost Lagos, Nigeria – July 30, 2025 – Beta Glass Plc, the leading manufacturer of glass packaging solutions in West and Central Africa, has announced its unaudited interim financial results for the first half of the year ended June 30th, 2025, recording strong and resilient growth despite macroeconomic challenges. H1 2025 Performance Overview Half Year 2025 Half Year 20-24 Var (+/_%) ₦ millions ₦ millions % Net Sales 78,232 47,884 63% Operating Profit 26,846 7,095 278% Operating Margin % 34% 15% Profit Before Tax 27,604 6,312 337% Profit After Tax 18,705 4,309 334% EBITDA 30,075 9,576 214% EBITDA (Margin %) 38% 20% EPS (₦ per share) 31.18 7.18 334% The strong H1 2025 performance was driven by increased market demand for glass packaging in our key sectors, strategic operational efficiencies and effective pricing, amidst several challenges, persistent inflationary pressures, and rising energy costs. Speaking on the results, Mr. Alexander Gendis, CEO of Beta Glass, said: 'We are very proud of our half year results; delivering double-digit growth in revenue and triple-digit growth in profitability despite a challenging environment. This performance is an affirmation of our market strength across West and Central Africa.' Mr. Gendis further noted the Company's continued investment in long-term growth drivers, including the deployment of a solar power plant at its Agbara facility in Ogun State, aimed at mitigating energy costs and advancing the Company's sustainability agenda. 'Looking ahead, we remain optimistic about the rest of 2025. We are confident that our focus on operational excellence, sustainable energy investments and expanding our product portfolio will continue to drive value for all stakeholders,' he added. Beta Glass remains committed to leveraging innovation, sustainability and partnerships to maintain its growth trajectory in the coming quarters. The Company continues to monitor external factors such as exchange rates and energy costs while optimising its supply chain for greater efficiency. For further details, the full unaudited interim financial statements are available on the Company's website. Headquartered in Lagos, Nigeria, the company operates across nine other African countries, including Ghana, Côte d'Ivoire, Sierra Leone, Liberia, Cameroon, South Africa, and Burkina Faso.
